Official websites use. Share sensitive information only on official, secure websites. Professor Joel M. Based on evidence from a number of large antihypertensive trials, 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 most guidelines acknowledge that combination therapy is needed to reduce blood pressure BP successfully to goal in the majority of patients; only a minority of patients achieve their BP goal with a single agent.
One logical approach would be to use 2 drugs from different classes and complementary mechanisms of action in combination. Such combinations may result in additional BP decreases and improved goal rates, compared with either agent used alone.
A combination of a CCB and an angiotensin II receptor blocker ARB is a rational approach for managing hypertension and there is increasing evidence that this combination is effective.
The trial was conducted in accordance with the Declaration of Helsinki and the ICH Harmonised Tripartite Guideline for Good Clinical Practice GCP and was approved by the health authority and institutional review boards or independent ethics committees in each participating country. Trial medication was to be taken once daily in the morning at approximately the same time each day. Other antihypertensive or concomitant medications known to affect BP were not permitted during the study.
BP measurements were performed using standard BP measuring equipment, consisting of a cuff with an inflatable bladder with a cloth sheath.
